...
首页> 外文期刊>Cardiovascular drugs and therapy >Long-term nitrate use in acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology nitrate evaluation program).
【24h】

Long-term nitrate use in acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology nitrate evaluation program).

机译:长期使用硝酸盐治疗急性心肌梗塞(日本心脏研究所心内科硝酸盐评估计划)。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The lack of any randomized controlled trials demonstrating a beneficial effect of nitrates for the secondary prevention of coronary artery disease leads to a negative recommendation in current practice guidelines. The aim of the present study was to examine the efficacy of nitrate therapy for the treatment of acute myocardial infarction (AMI) in the contemporary revascularization era. METHODS AND RESULTS: Of 2,736 consecutive patients with AMI (1,677 on nitrate therapy and 1,059 control patients not receiving nitrates), 1,766 patients were matched according to a propensity score (883 receiving nitrates and 883 control subjects). Before propensity score matching, the patients treated with nitrates were significantly older, had a higher Killip class, and underwent less aggressive revascularization and less modern pharmacotherapy compared with the patients who were not given nitrates. A total of 117 patients (11.0%) died in the control group and 317 patients (18.9%) in the nitrate group (hazard ratio, 1.70; 95% CI, 1.38-2.10; P < 0.001) during a 5-year follow-up period. In contrast, among propensity score-matched patients, 110 patients (12.5%) died in the control group and 126 patients died (14.3%) in the nitrate group (hazard ratio, 1.06; 95% CI 0.82-1.36, P = 0.678). The 1-, 3- and 5-year cumulative mortality rates (Kaplan-Meier method) were respectively 4.5%, 9.8%, and 14.1% in the control group versus 5.2%, 9.8%, and 14.8% in the nitrate group. There were also no statistical or clinical differences between the two matched groups with regard to the other endpoints assessed. CONCLUSIONS: Our results suggest that nitrate therapy does not increase mortality and cardiac events in AMI patients. Our results differ from those of previous observational studies, suggesting that new prospective randomized clinical trials are needed in the current revascularization era.
机译:背景:缺乏任何表明硝酸盐对冠心病的二级预防具有有益作用的随机对照试验,导致当前实践指南中出现负面建议。本研究的目的是研究硝酸盐疗法在当代血运重建时代治疗急性心肌梗塞(AMI)的功效。方法和结果:连续2736例AMI患者(其中1677例接受硝酸盐治疗,1,059例未接受硝酸盐的对照组),根据倾向评分匹配了1766例患者(883例接受硝酸盐和883例对照)。与未给予硝酸盐治疗的患者相比,在倾向得分匹配之前,接受硝酸盐治疗的患者年龄较大,基利普等级较高,并且进行的血管重建术和现代药物治疗较少。在5年的随访中,对照组共有117例患者(11.0%)死亡,硝酸盐组有317例患者(18.9%)死亡(危险比,1.70; 95%CI,1.38-2.10; P <0.001)-上升期。相比之下,在倾向得分匹配的患者中,硝酸盐组死亡110例(12.5%),硝酸盐组死亡126例(14.3%)(危险比1.06; 95%CI 0.82-1.36,P = 0.678) 。对照组的1年,3年和5年累积死亡率(Kaplan-Meier方法)分别为4.5%,9.8%和14.1%,而硝酸盐组分别为5.2%,9.8%和14.8%。就其他评估终点而言,两个匹配组之间也没有统计学或临床差异。结论:我们的结果表明硝酸盐疗法不会增加AMI患者的死亡率和心脏事件。我们的结果与之前的观察研究不同,这表明在当前的血运重建时代需要新的前瞻性随机临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号